|
ACVR1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.11022302462516E-16 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.44089209850063E-16 |
| Normal-vs-Stage2 |
2.613800E-02 |
| Normal-vs-Stage3 |
4.83160000896987E-09 |
| Normal-vs-Stage4 |
3.42509998141338E-09 |
| Stage1-vs-Stage2 |
1.355720E-02 |
| Stage1-vs-Stage3 |
2.173800E-01 |
| Stage1-vs-Stage4 |
4.411400E-01 |
| Stage2-vs-Stage3 |
8.481600E-02 |
| Stage2-vs-Stage4 |
5.553600E-02 |
| Stage3-vs-Stage4 |
6.938400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.624810E-04 |
| Normal-vs-Asian |
1.18769999946089E-07 |
| Caucasian-vs-AfricanAmerican |
9.768200E-01 |
| Caucasian-vs-Asian |
2.075200E-01 |
| AfricanAmerican-vs-Asian |
4.218200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.58330004662588E-09 |
| Normal-vs-Female |
1.62503344114384E-12 |
| Male-vs-Female |
9.083600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.6251444634463E-12 |
| Normal-vs-Age(41-60Yrs) |
6.22391027604863E-13 |
| Normal-vs-Age(61-80Yrs) |
7.618600E-04 |
| Normal-vs-Age(81-100Yrs) |
3.878100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.550500E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.81679999999851E-05 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.252170E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.098300E-03 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.644000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.211400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.583600E-01 |
| Classical-VS-Follicular |
1.11022302462516E-16 |
| Classical-VS-Other |
4.755200E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
1.67720282107098E-11 |
| Tall-VS-Other |
3.037000E-01 |
| Tall-VS-Normal |
3.24750004665475E-10 |
| Follicular-VS-Other |
8.176900E-03 |
| Follicular-VS-Normal |
8.106400E-01 |
| Other-VS-Normal |
8.862200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.33939999886246E-08 |
| Normal-vs-N1 |
2.74830000002169E-06 |
| N0-vs-N1 |
1.150000E-01 |
|
|
